Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

This is written in the approval document.

Reimbursement

ODMS

ODMS; 2019-03-01 (IV); 2024-06-01 (SC)

Citation

Atezolizumab Monotherapy, 2025, version number 14, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6644/544_v14_Atezolizumab_21_Day_Monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) EGFR Somatic variants Non-Small Cell Lung Cancer Atezolizumab
HSE (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab